If you follow developments in interventional medicine, you’ve probably noticed a shift. Procedures that were once reserved for oncology and acute hemorrhage are migrating into an entirely different clinical territory: chronic musculoskeletal pain.
Table of Contents
The catalyst is a deceptively simple insight. Many common chronic pain conditions — knee osteoarthritis, tennis elbow, frozen shoulder, plantar fasciitis — share a pathological feature that has been hiding in plain sight: abnormal neovascularization of the affected tissue. And where there are abnormal blood vessels, there is an opportunity for embolization.
The implications of this are significant, both for the patients living with these conditions and for the clinicians trying to help them. Let’s trace the thread.
The Okuno Paradigm
The story begins with Dr. Yuji Okuno, an interventional radiologist based in Tokyo who made a career-altering observation in the early 2010s. Okuno recognized that the abnormal blood vessels found in chronically painful joints and tendons weren’t just bystanders — they were active participants in the pain cycle.
His reasoning drew from established vascular biology. When tissue is damaged, the body initiates angiogenesis to support repair. In most cases, this process self-regulates: the tissue heals, the new vessels regress, and the area returns to normal. But in certain chronic conditions, the angiogenic process continues unchecked. The resulting neovascular clusters don’t aid repair. Instead, they sustain inflammation by delivering a continuous supply of inflammatory mediators, and — crucially — they bring new sensory nerve fibers that amplify pain signaling.
Okuno’s contribution was to apply a well-established interventional tool to this problem. If the abnormal blood vessels were driving the pain, what would happen if you selectively blocked them?
The answer, demonstrated across a growing body of clinical research, is that the pain resolves — often dramatically, and often durably.
Genicular Artery Embolization: The Proof of Concept
The condition where this approach has gained the most traction is chronic knee osteoarthritis, treated via genicular artery embolization (GAE).
Knee OA is a massive clinical problem. Over 30 million Americans live with it, and for many, the treatment path eventually narrows to total knee arthroplasty — a major surgery with extended recovery that not all patients want, can tolerate, or medically qualify for.
GAE addresses the inflammatory neovascularization within and around the knee joint. Using fluoroscopic guidance, a microcatheter is navigated through a small arterial puncture to the genicular arteries supplying the abnormal vessels in the synovium and periarticular tissues. Calibrated microspheres are delivered to selectively occlude these vessels, interrupting the inflammatory pain cycle without affecting normal knee vasculature.
The clinical results have been robust enough to attract multi-center randomized trials — a milestone that typically signals a technique’s transition from investigational to mainstream. Published data consistently shows significant pain reduction and functional improvement in 70 to 80 percent of treated patients, with results sustained at one-year and two-year follow-up.
Importantly, GAE doesn’t preclude future knee replacement. It preserves that option while giving patients meaningful pain relief in the interim — months or years of improved function that wouldn’t have been available otherwise.
Plantar Fasciitis: The Same Biology, Different Location
The extension from knee to foot was logical. Chronic plantar fasciitis — heel pain lasting six months or more despite conservative treatment — exhibits the same neovascular pathology observed in knee OA. Doppler ultrasound studies of chronically painful plantar fasciae consistently demonstrate increased vascularity at the calcaneal insertion, and histological examination confirms the presence of neovascular clusters with associated neoinnervation.
Plantar fasciitis embolization (PFE) follows the same procedural principles as GAE, adapted for the foot’s vascular anatomy. Access is typically gained through the dorsalis pedis or posterior tibial artery at the ankle, and microspheres are delivered to the feeding vessels of the neovascular clusters around the plantar fascia.
Published outcomes are encouraging. In Okuno’s series of 66 patients with refractory plantar fasciitis — individuals who had failed physical therapy, orthotics, corticosteroid injections, and in some cases shockwave therapy — 85 percent achieved clinically meaningful pain reduction at three months, with sustained improvement at one year. Mean pain scores dropped from approximately 7.5 to 2.0 on a 10-point scale.
The recovery profile is remarkably light. No general anesthesia, no immobilization, no crutches. Patients walk out of the procedure room and return to normal activity within days. Pain improvement is gradual over two to eight weeks as the inflammatory cycle winds down following vascular occlusion.
Why This Matters Beyond the Individual Patient
The broader significance of embolization’s expansion into musculoskeletal medicine extends beyond any single condition.
It fills a treatment gap. For both knee OA and chronic plantar fasciitis, there has long been a precipitous jump in invasiveness between conservative management and surgical intervention. Embolization occupies the middle ground — more definitive than injections or physical therapy, far less invasive than joint replacement or fasciotomy.
It reframes the pathophysiology. Thinking of chronic musculoskeletal pain as partly a vascular problem — driven by abnormal angiogenesis and neoinnervation — opens new therapeutic avenues and helps explain why anti-inflammatory approaches often fail in chronic cases. The inflammation isn’t the root cause; the blood vessels sustaining it are.
It enables collaboration. Embolization brings vascular and interventional specialists into the musculoskeletal care team, creating a collaborative model where orthopedic surgeons, rheumatologists, podiatrists, and vascular surgeons each contribute their expertise. Practitioners like Dr. David Fox, a board-certified vascular surgeon in Manhattan with more than 28 years of experience, work within this model — receiving referrals from podiatrists and orthopedists for patients whose chronic pain has resisted conventional management.
The Road Ahead
Embolization for chronic musculoskeletal pain is still in a relatively early stage of adoption in the United States, though it has been practiced in Japan and parts of Europe for over a decade. Multi-center randomized controlled trials for GAE are ongoing, and similar trial designs for PFE are anticipated as the evidence base grows.
The procedure hasn’t yet entered most clinical practice guidelines, and many referring physicians are still learning about it. But the trajectory is consistent with how interventional techniques have historically evolved — from case series to larger prospective studies to guideline inclusion, driven by reproducible outcomes and favorable safety profiles.
For patients and clinicians navigating chronic musculoskeletal conditions that have plateaued on conservative care, embolization represents a rational, evidence-informed option worth discussing.
This article was written for WHN by Parker, who is a health and wellness content writer with a strong interest in evidence-based healthcare, longevity, preventive medicine, and emerging medical technologies. Their work focuses on creating accurate, informative content that helps readers better understand health innovations, patient care, and strategies for long-term well-being.
As with anything you read on the internet, this article on plantar fasciitis should not be construed as medical advice; please talk to your doctor or primary care provider before changing your wellness routine. WHN neither agrees nor disagrees with any of the materials posted. This article is not intended to provide a medical diagnosis, recommendation, treatment, or endorsement.
Opinion Disclaimer: The views and opinions expressed in this article on plantar fasciitis are those of the author and do not necessarily reflect the official policy of WHN. Any content provided by guest authors is of their own opinion and is not intended to malign any religion, ethnic group, club, organization, company, individual, or anyone or anything else. The Food and Drug Administration has not evaluated these statements.
